The present invention provides a compound of formula (I): wherein V represents NR.sup.5, O, S, SO or S(O).sub.2; W and X each independently represent CH or N; Y represents N, CH or C--Ar.sub.2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C--Ar.sub.2, with the proviso that when Y is N or CH then Z is C--Ar.sub.2, and with the further proviso that when Y is C--Ar.sub.2 then Z is CH; Ar.sub.1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar.sub.2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R.sup.1 represents halogen, hydroxy, oxo, C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, haloC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkoxy, haloC.sub.1-6alkoxy, hydroxyC.sub.1-6alkoxy, C.sub.3-7cycloalkyl, C.sub.3-7cycloalkoxy, C.sub.3-5cycloalkylC.sub.1-4alkyl, cyano, nitro, SR.sup.6, SOR.sup.6, SO.sub.2R.sup.6, COR.sup.6, NR.sup.3COR.sup.6, CONR.sup.3R.sup.4, NR.sup.3SO.sub.2R.sup.6, SO.sub.2NR.sup.3R.sup.4, --(CH.sub.2).sub.mcarboxy, esterified --(CH.sub.2).sub.mcarboxy or --(CH.sub.2).sub.mNR.sup.3R.sup.4; R.sup.2 represents hydrogen, halogen, hydroxy, C.sub.1-6alkyl, haloC.sub.1-6alkyl, C.sub.3-7cycloalkyl, C.sub.1-6alkoxy, haloC.sub.1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C.sub.1-6alkyl, haloC.sub.1-6alkyl, C.sub.3-7cycloalkyl, C.sub.1-6alkoxy or haloC.sub.1-6alkoxy; R.sup.3 and R.sup.4 are each independently hydrogen, C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, C.sub.3-7cycloalkyl or fluoroC.sub.1-6alkyl; or R.sup.3 and R.sup.4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C.sub.1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O).sub.2, or NR.sup.5; R.sup.5 represents hydrogen, C.sub.1-4alkyl, hydroxyC.sub.1-4alkyl or C.sub.1-4alkoxyC.sub.1-4alkyl; R.sup.6 represents hydrogen, C.sub.1-6alkyl, fluoroC.sub.1-6alkyl, C.sub.3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C.sub.1-6alkyl, haloC.sub.1-6alkyl, C.sub.3-7cycloalkyl, C.sub.1-6alkoxy or haloC.sub.1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it. ##STR00001##